Clin Oncol | Volume 8, Issue 1 | Research Article | Open Access

Efficacy of Palliative Metronomic Cyclophosphamide Chemotherapy: A Retrospective Analysis of 15 Years of Experience at CHU UCL Namur, Site Godinne

Percy C1, Rosier G1, Barani C1, Regnier M2, Faugeras L1, Collette F1, Gilliaux Q1 and D’Hondt L1*

1Department of Oncology, CHU UCL Namur Site Godinne, Yvoir, Belgium
2Scientific Support Unit, CHU UCL Namur Site Godinne, Yvoir, Belgium

*Correspondance to: Lionel D’Hondt 

Fulltext PDF


Background: The use of metronomic chemotherapy in routine clinical practice is still debated. This retrospective analysis was performed to evaluate the benefit-risk balance of this treatment in a palliative setting for unselected metastatic cancer patients. Patients and Methods: We performed a retrospective analysis of all patients who received palliative metronomic Cyclophosphamide (mCTX) for metastatic solid tumors between 2005 and 2020 at our institution.
Results: A total of 82 patients received palliative mCTX at a dose of 50 to 150 mg/day either continuously or with a pause of 1 week per cycle. The most frequent diagnoses were colorectal (22%), prostate (20%), and ovarian cancer (16%). Nearly 20% of the heavily pretreated patients achieved clinical benefit at first assessment. Median duration of treatment was 2.5 months (range
0.1 to 118 months). Median progression-free survival was 2.5 months (range 0.1 to 118 months). Median overall survival was 4.6 months (range 0.2 to 130 months). These results increased with additional concomitant therapy and in patients with previous hormone therapy. Only 7% of patients stopped treatment due to toxicity.
Conclusion: This retrospective study shows that palliative mCTX has efficacy in some unselected patients, with low toxicity. Additional concomitant therapy is possible and offers an increased benefit. This treatment can be proposed in some patients, though it is unclear which patients will benefit most.


Cyclophosphamide; Metronomic chemotherapy; Cancer metastasis; Palliative care


Percy C, Rosier G, Barani C, Regnier M, Faugeras L, Collette F, et al. Efficacy of Palliative Metronomic Cyclophosphamide Chemotherapy: A Retrospective Analysis of 15 Years of Experience at CHU UCL Namur, Site Godinne. Clin Oncol. 2023;8:1984..

Subscribe to Our Newsletter